ALHAMBRA, Calif., Dec. 18, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that effective on December 15, 2023, the Compensation Committee of ApolloMed's Board of Directors (the "Committee") granted a total of 38,779 shares of restricted common stock to eight newly-hired non-executive employees, under the Apollo Medical Holdings, Inc. Employment Inducement Award Plan (the "Inducement Plan"). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of the Company (or following a bona fide period of non-employment) as an inducement material to such individuals' commencement of employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).
Of the restricted stock granted, 22,182 shares will vest, subject to continued employment, over four years in substantially equal annual installments on the first, second, third and fourth anniversaries of the grant date, and 16,597 shares will vest, subject to continued employment, based on the achievement of the applicable performance targets and the same time-based vesting conditions as the other shares of restricted stock granted. The restricted stock is subject to the terms and conditions of the Inducement Plan and an award agreement covering each grant.
About Apollo Medical Holdings, Inc.
ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver outcomes-based medical care to patients in a cost-effective manner.
Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models. For more information, please visit www.apollomed.net.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
(626) 943-6491
This email address is being protected from spambots. You need JavaScript enabled to view it.
Asher Dewhurst, ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$37.16 |
Daily Volume: | 14,306 |
February 27, 2024 January 24, 2024 November 07, 2023 November 07, 2023 August 07, 2023 |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB